Cell therapy biotech Aurion gets $120M to restore vision and revamp organ donor economics

Organ donation has long been a matter of demand outstripping supply, but Aurion Biotech aims to improve the supply part of the equation with a cell therapy. Aurion’s technology turns a single donated cornea into treatments for up to 100 patients and the startup now has $120 million for clinical trials.